2020/2021: THE CLUSTER IS COMMITTED TO SUPPORTING ITS MEMBERS
Faced with the current health crisis, cluster members rallied strongly and have been working intensively on the front line, whether in testing, treatments, vaccines or patient care. To help stimulate their innovation strategies, foster group-wide discussion and support new opportunities for partnership agreements, Atlanpole Biotherapies has:
- Organised 24 events that brought together over 1,500 participants,
- Supported the set-up, approval and funding of 30 collaborative projects,
- Offered its members the opportunity to attend 6 international trade shows.
Lastly, on a national scale, jointly with the 5 other French healthcare clusters, Atlanpole Biotherapies helped to draft SME recommendations as part of the national recovery plan.
ATLANPOLE BIOTHERAPIES IS GROWING EXPONENTIALLY
The cluster currently counts 220 members, 32 of whom joined in 2021.
In addition to its proactive membership policy, the cluster is vigorously pursuing an ambitious strategy designed to amplify its members’ level of excellence:
- By consolidating strategic partnerships in order to federate scientific communities around the cluster’s key focus areas and foster the development of collaborative projects
- By developing funding tools designed specifically to boost the growth of enterprises.
The cluster is developing this strategy around its 6 key strategic focus areas – Immunotherapeutics, Radiopharmaceuticals and Regenerative Medicine, Digital Technologies for Innovative Therapies, Nutrition and Microbiota, Animal Health.
AND WORKING TO BUILD A SOVEREIGN FRANCE AND EUROPE IN TERMS OF HEALTHCARE
Innovation is driven predominantly by SMEs; the challenge lies in their ability to scale up to become larger-sized companies (future “unicorns”).
France currently counts 2,000 SMEs (40% biotech, 50% medtech and 10% e-health).
THE GRAND OUEST REGION IS STRONGLY PLACED IN THIS RACE.
Today, the 20 most promising French companies are developing treatments that have the potential to treat 250 million patients worldwide. By 2030, the healthcare sector will represent 130,000 new job opportunities and a projected potential turnover of 40 billion euros (source: Boston Consulting Group, 2017).
The health crisis nevertheless revealed that, despite its many advantages, France has failed to foster adequate growth in the healthcare industry value chain. This reinforces the conviction that a strong economy cannot exist without a strong productive sector. The health and economic crisis has shone a spotlight on the weak points in our production and supply chains.
In several strategic areas, both for our industry and for the life of the French people, our self-sufficiency and economic sovereignty have been proved lacking. We are too dependent on globalised production chains, international logistics networks and trade-offs involving the sovereignty of other countries. Based on this observation, the French government launched an ambitious programme – France Relance – aimed at regaining control over the levers for our current and future resilience and meeting the challenges of relocating production capabilities.
160 PROJECTS NATIONWIDE ARE FRANCE RELANCE WINNERS – INCLUDING 50 PROJECTS IN HEALTHCARE SECTOR, 11 OF WHICH ARE RUN BY CLUSTER MEMBERS.
11 out of the 50 winning projects are run by cluster members. These represent 11 production units to be built in the Grand Ouest region. Our region is making a significant contribution to efforts to help France regain its sovereignty in terms of Healthcare.
- Over 220 members in Brittany, Pays de la Loire, Centre Val de Loire
- Including over 150 businesses
- 4 publicly listed companies
- 6 CHU involved
- 65,000 jobs including
- 6,500 private-sector jobs in the field of R&D
- 25% of jobs nationwide concerning SME with less than 50 employees
- 823 projects approved since the start
OVERVIEW OF ATLANPOLE BIOTHERAPIES
Atlanpole Biotherapies is an interregional competitiveness cluster covering the Pays de la Loire – Brittany – Centre Val de Loire regions, certified by the Ministry of Industry in July 2005. Atlanpole Biotherapies
pools the expertise of a large group of laboratories, platforms and businesses, providing a comprehensive, relevant and competitive public-private offer that covers the whole biopharmaceuticals value chain from the discovery of targets up to the final clinical assessment.
The cluster also plays a role in shaping the healthcare industry of tomorrow, structured around 6 fields of excellence:
- Regenerative medicine
- Clinical nutrition & microbiota
- Animal health
- Digital technologies for innovative therapies